Multiple Myeloma

Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
Sat, 12/7/19 - 11:47 pm
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
AbbVie signs potential $2.4bn cancer immunotherapy deal with Harpoon
Pharmaforum
Thu, 11/21/19 - 10:39 am
AbbVie
Harpoon Therapeutics
R&D
BCMA
Multiple Myeloma
Takeda scores a win for Ninlaro as it aims to pioneer 'switch' maintenance in multiple myeloma
Fierce Pharma
Fri, 11/8/19 - 10:57 am
Takeda
Ninlaro
Multiple Myeloma
clinical trials
J&J's Darzalex makes FDA history with another myeloma nod in new patients
Fierce Pharma
Fri, 09/27/19 - 09:56 am
JNJ
Darzalex
FDA
Multiple Myeloma
Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win
Fierce Pharma
Mon, 09/16/19 - 09:25 am
Amgen
Kyprolis
JNJ
Darzalex
Multiple Myeloma
Italian gene therapy player draws new investor from China for its answer to CAR-T relapses
Endpoints
Tue, 09/10/19 - 11:37 pm
gene therapy
Genenta Science
clinical trials
glioblastoma
Multiple Myeloma
CAR-T
GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test
Fierce Biotech
Fri, 08/23/19 - 10:14 am
GSK
anti-BCMA
Multiple Myeloma
belantamab mafodotin
Karyopharm’s Xpovio nabs myeloma nod despite checkered past. But 5th line?
Fierce Pharma
Mon, 07/8/19 - 08:07 pm
Karyopharm
FDA
Multiple Myeloma
Xpovio
Selinexor
After negative panel vote, FDA approves Karyopharm's multiple myeloma drug
BioCentury
Fri, 07/5/19 - 01:36 pm
Karyopharma
Xpovio
Selinexor
FDA
Multiple Myeloma
FDA quickly approves J&J’s Darzalex in multiple myeloma
Pharmaforum
Fri, 06/28/19 - 12:32 pm
JNJ
Janssen
FDA
Darzalex
Multiple Myeloma
FDA lifts hold on AbbVie multiple myeloma study
Biopharma Dive
Tue, 06/25/19 - 07:19 pm
FDA
AbbVie
Venclexta
clinical trials
Multiple Myeloma
AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud
Endpoints
Mon, 06/24/19 - 10:54 am
AbbVie
Venclexta
Multiple Myeloma
FDA
clinical trials
J&J bags $150M option on Genmab's Darzalex successor
Fierce Biotech
Tue, 06/11/19 - 09:34 am
Genmab
JNJ
Darzalex
Multiple Myeloma
drug development
Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients
TheStreet.com
Wed, 06/5/19 - 09:35 am
Amgen
AMG 420
Multiple Myeloma
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
#ASCO19: Sanofi sets the stage for a late arrival of their multiple myeloma drug isatuximab — with J&J and Genmab laying in wait
Endpoints
Sun, 06/2/19 - 01:18 pm
Sanofi
Multiple Myeloma
isatuximab
ASCO 2019
Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm
Fierce Pharma
Fri, 05/24/19 - 04:35 pm
Amgen
sales poaching
drug reps
Karyopharm Therapeutics
Multiple Myeloma
Selinexor
After years of delays, NICE backs Celgene’s Revlimid in first-line MM
Pharmaforum
Fri, 05/17/19 - 07:18 pm
Celgene
Revlimid
Multiple Myeloma
NICE
NHS
England
Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses
Fierce Biotech
Fri, 05/3/19 - 10:45 am
Celgene
Bluebird Bio
bb2121
cell therapy
CAR-T
Multiple Myeloma
Roche throws in the towel on Tecentriq bladder, myeloma trials
Fierce Pharma
Fri, 04/19/19 - 06:16 pm
Roche
Tecentriq
bladder cancer
Multiple Myeloma
clinical trials

Pages